Strata Critical Medical Reports Strong 2025 Results with 34% Revenue Growth and Significant EBITDA Improvement
SRTA has more than doubled off its 52-week low of $2.35.
Summary
Strata Critical Medical, Inc. announced strong 2025 financial results, including 34.3% revenue growth and a 274% surge in Adjusted EBITDA, driven by its strategic shift to medical logistics and clinical services.
Key Events · Earnings and Guidance · SRTA
-
Strong Financial Performance
Reported a 34.3% increase in revenue to $197.1 million and a 274% increase in Adjusted EBITDA from continuing operations to $14.1 million for the fiscal year 2025. The company also swung to a net income of $41.3 million from a net loss of $27.3 million in 2024.
-
Strategic Business Transformation
Completed the divestiture of its Passenger business for $75.4 million (net proceeds $70.2 million) and acquired Keystone Perfusion Services, LLC for $111.3 million cash and $16.8 million in stock, focusing entirely on time-critical medical logistics and clinical services.
-
Enhanced Liquidity
Secured a new $30 million secured asset-based revolving credit facility in January 2026, with an accordion feature for an additional $20 million, providing significant financial flexibility. Total liquidity stood at $61.2 million as of December 31, 2025.
-
Effective Internal Controls
Management concluded that internal control over financial reporting was effective as of December 31, 2025, with an unqualified opinion from Deloitte & Touche LLP, excluding the recently acquired Keystone's controls.
Analysis · SRTA · Industrial Applications And Services
Strata Critical Medical, Inc. reported robust financial results for the fiscal year ended December 31, 2025, building on the preliminary announcement made in the recent 8-K filing. The company achieved substantial revenue growth of 34.3% and a significant 274% increase in Adjusted EBITDA from continuing operations, swinging from a net loss to a net income of $41.3 million. This strong performance underscores the successful strategic pivot to a focused medical logistics and clinical services provider, following the divestiture of its Passenger business and the acquisition of Keystone Perfusion Services, LLC in 2025. The company also enhanced its liquidity with a new $30 million secured revolving credit facility and reported effective internal controls, signaling operational stability and a positive outlook for its specialized healthcare market.
At the time of this filing, SRTA was trading at $4.75 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $409.8M. The 52-week trading range was $2.35 to $6.02. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.